DekaBank Deutsche Girozentrale - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 210 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.39 and the average weighting 0.3%.

Quarter-by-quarter ownership
DekaBank Deutsche Girozentrale ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,950
+12.3%
50,0000.0%0.00%0.0%
Q2 2023$1,737
-6.2%
50,0000.0%0.00%
-20.0%
Q1 2023$1,851
-57.6%
50,000
-35.0%
0.01%
-58.3%
Q4 2022$4,362
-99.9%
76,9000.0%0.01%
+33.3%
Q3 2022$3,017,000
-12.4%
76,9000.0%0.01%
-10.0%
Q2 2022$3,446,000
+11.4%
76,9000.0%0.01%
+25.0%
Q1 2022$3,093,000
-0.7%
76,9000.0%0.01%0.0%
Q4 2021$3,115,000
+198.9%
76,900
+193.5%
0.01%
+166.7%
Q3 2021$1,042,000
-12.4%
26,2000.0%0.00%0.0%
Q2 2021$1,190,000
+11.0%
26,2000.0%0.00%
-25.0%
Q1 2021$1,072,000
-2.7%
26,2000.0%0.00%0.0%
Q4 2020$1,102,000
+53.1%
26,200
-4.7%
0.00%
+33.3%
Q3 2020$720,000
+66.3%
27,500
-3.5%
0.00%0.0%
Q3 2019$433,000
-42.9%
28,500
-36.7%
0.00%
-25.0%
Q2 2019$758,000
+51.0%
45,000
+63.6%
0.00%
+33.3%
Q1 2019$502,000
+55.4%
27,500
+22.2%
0.00%
+50.0%
Q4 2018$323,000
-35.7%
22,500
-18.2%
0.00%
-33.3%
Q3 2018$502,000
+4.6%
27,500
-2.5%
0.00%0.0%
Q2 2018$480,000
-59.9%
28,200
-55.4%
0.00%
-62.5%
Q1 2018$1,197,000
+50.9%
63,200
-5.0%
0.01%
+33.3%
Q4 2017$793,0000.0%66,5000.0%0.01%0.0%
Q3 2017$793,000
-8.1%
66,5000.0%0.01%
-14.3%
Q2 2017$863,000
-0.3%
66,5000.0%0.01%
-12.5%
Q1 2017$866,000
+20.9%
66,500
-7.9%
0.01%0.0%
Q4 2016$716,000
-9.8%
72,200
+8.2%
0.01%
-11.1%
Q3 2016$794,000
+41.3%
66,7000.0%0.01%
+50.0%
Q2 2016$562,000
-1.6%
66,700
+8.1%
0.01%
-14.3%
Q1 2016$571,000
-49.6%
61,700
-5.1%
0.01%
-46.2%
Q4 2015$1,132,000
+31.6%
65,000
+1.6%
0.01%
+30.0%
Q3 2015$860,000
-37.5%
64,000
+4.9%
0.01%
-37.5%
Q2 2015$1,377,000
+63.9%
61,000
+3.7%
0.02%
+60.0%
Q1 2015$840,000
+32.5%
58,800
-12.8%
0.01%
+25.0%
Q4 2014$634,000
-5.1%
67,400
-8.2%
0.01%
-11.1%
Q3 2014$668,000
-5.2%
73,400
+2.8%
0.01%
-18.2%
Q2 2014$705,000
-20.6%
71,400
+2.1%
0.01%
-21.4%
Q1 2014$888,000
-9.3%
69,900
+8.7%
0.01%
-12.5%
Q4 2013$979,000
+40.1%
64,300
+1.6%
0.02%
+33.3%
Q3 2013$699,00063,3000.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2018
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders